What does this research mean for the field?

Effective management of Pythium insidiosum keratitis requires a transition from conventional antifungal agents to targeted antibacterial-based therapies, such as linezolid and azithromycin. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review current pharmacotherapeutic strategies, mechanisms of antifungal resistance, and emerging targeted anti-oomycete therapies for Pythium insidiosum keratitis.

September 14, 2026Expert Opinion on Pharmacotherapy

Pharmacotherapy of Pythium insidiosum keratitis – a contemporary update

View Full Paper

Ask AI

Bookmark

Authors

BGBharat Gurnani KKKirandeep Kaur

Discussion

Member takes

Overview

Review reveals targeted antibacterial therapy improves outcomes in Pythium insidiosum keratitis, indicating the need to abandon ineffective standard antifungals.

Key Points

To review current pharmacotherapeutic strategies, mechanisms of antifungal resistance, and emerging targeted anti-oomycete therapies for Pythium insidiosum keratitis.
Searched PubMed, Scopus, Embase, and Web of Science databases for literature on drug susceptibility profiles and clinical management of Pythium insidiosum keratitis.
Synthesized evidence regarding antibacterial regimens, adjunctive anti-collagenolytic and anti-inflammatory interventions, and emerging precision medicine technologies.
Pythium insidiosum is an oomycete lacking ergosterol in its cell membrane, which renders conventional antifungal agents intrinsically ineffective and leads to rapid corneal stromal melting.
Antibacterial-based regimens, specifically linezolid and azithromycin, provide therapeutic efficacy against the pathogen alongside adjunctive anti-collagenolytic therapies.
Shifting clinical practice from empirical antifungal therapy to rapid molecular diagnosis and targeted antibacterial delivery improves globe salvage rates and visual outcomes.

Cite This Study

Gurnani et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3aa0926e14a848b2bf4 https://doi.org/10.1080/14656566.2026.2734123

View Full Paper

Ask AI

Bookmark

September 14, 2026Expert Opinion on Pharmacotherapy

Pharmacotherapy of Pythium insidiosum keratitis – a contemporary update

View Full Paper

Ask AI

Bookmark

Authors

BGBharat Gurnani KKKirandeep Kaur

Discussion

Member takes

Overview

Review reveals targeted antibacterial therapy improves outcomes in Pythium insidiosum keratitis, indicating the need to abandon ineffective standard antifungals.

Key Points

To review current pharmacotherapeutic strategies, mechanisms of antifungal resistance, and emerging targeted anti-oomycete therapies for Pythium insidiosum keratitis.
Searched PubMed, Scopus, Embase, and Web of Science databases for literature on drug susceptibility profiles and clinical management of Pythium insidiosum keratitis.
Synthesized evidence regarding antibacterial regimens, adjunctive anti-collagenolytic and anti-inflammatory interventions, and emerging precision medicine technologies.
Pythium insidiosum is an oomycete lacking ergosterol in its cell membrane, which renders conventional antifungal agents intrinsically ineffective and leads to rapid corneal stromal melting.
Antibacterial-based regimens, specifically linezolid and azithromycin, provide therapeutic efficacy against the pathogen alongside adjunctive anti-collagenolytic therapies.
Shifting clinical practice from empirical antifungal therapy to rapid molecular diagnosis and targeted antibacterial delivery improves globe salvage rates and visual outcomes.

Cite This Study

Gurnani et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3aa0926e14a848b2bf4 https://doi.org/10.1080/14656566.2026.2734123

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark